These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 25719328)

  • 1. Quantitative detection of amyloid-β peptides by mass spectrometry: state of the art and clinical applications.
    Bros P; Delatour V; Vialaret J; Lalere B; Barthelemy N; Gabelle A; Lehmann S; Hirtz C
    Clin Chem Lab Med; 2015 Sep; 53(10):1483-93. PubMed ID: 25719328
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Preanalytical approaches to improve recovery of amyloid-β peptides from CSF as measured by immunological or mass spectrometry-based assays.
    Schauer SP; Mylott WR; Yuan M; Jenkins RG; Rodney Mathews W; Honigberg LA; Wildsmith KR
    Alzheimers Res Ther; 2018 Nov; 10(1):118. PubMed ID: 30486870
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Isobaric Quantification of Cerebrospinal Fluid Amyloid-β Peptides in Alzheimer's Disease: C-Terminal Truncation Relates to Early Measures of Neurodegeneration.
    Rogeberg M; Almdahl IS; Wettergreen M; Nilsson LN; Fladby T
    J Proteome Res; 2015 Nov; 14(11):4834-43. PubMed ID: 26452689
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Quantitative analysis of amyloid beta peptides in cerebrospinal fluid of Alzheimer's disease patients by immunoaffinity purification and stable isotope dilution liquid chromatography/negative electrospray ionization tandem mass spectrometry.
    Oe T; Ackermann BL; Inoue K; Berna MJ; Garner CO; Gelfanova V; Dean RA; Siemers ER; Holtzman DM; Farlow MR; Blair IA
    Rapid Commun Mass Spectrom; 2006; 20(24):3723-35. PubMed ID: 17117458
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antibody-free detection of amyloid beta peptides biomarkers in cerebrospinal fluid using capillary isotachophoresis coupled with mass spectrometry.
    Crosnier de Lassichère C; Duc Mai T; Taverna M
    J Chromatogr A; 2019 Sep; 1601():350-356. PubMed ID: 31101465
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mass spectrometry analysis of the diversity of Aβ peptides: difficulties and future perspectives for AD biomarker discovery.
    Zakharova NV; Bugrova AE; Kononikhin AS; Indeykina MI; Popov IA; Nikolaev EN
    Expert Rev Proteomics; 2018 Oct; 15(10):773-775. PubMed ID: 30253669
    [No Abstract]   [Full Text] [Related]  

  • 7. Simultaneous analysis of cerebrospinal fluid biomarkers using microsphere-based xMAP multiplex technology for early detection of Alzheimer's disease.
    Kang JH; Vanderstichele H; Trojanowski JQ; Shaw LM
    Methods; 2012 Apr; 56(4):484-93. PubMed ID: 22503777
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Qualification of a surrogate matrix-based absolute quantification method for amyloid-β₄₂ in human cerebrospinal fluid using 2D UPLC-tandem mass spectrometry.
    Korecka M; Waligorska T; Figurski M; Toledo JB; Arnold SE; Grossman M; Trojanowski JQ; Shaw LM
    J Alzheimers Dis; 2014; 41(2):441-51. PubMed ID: 24625802
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Round robin test on quantification of amyloid-β 1-42 in cerebrospinal fluid by mass spectrometry.
    Pannee J; Gobom J; Shaw LM; Korecka M; Chambers EE; Lame M; Jenkins R; Mylott W; Carrillo MC; Zegers I; Zetterberg H; Blennow K; Portelius E
    Alzheimers Dement; 2016 Jan; 12(1):55-9. PubMed ID: 26206625
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Amyloid β (Aβ) and phospho-tau (p-tau) as diagnostic biomarkers in Alzheimer's disease.
    Prvulovic D; Hampel H
    Clin Chem Lab Med; 2011 Mar; 49(3):367-74. PubMed ID: 21342022
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Diagnostic Accuracy of Cerebrospinal Fluid Amyloid-β Isoforms for Early and Differential Dementia Diagnosis.
    Struyfs H; Van Broeck B; Timmers M; Fransen E; Sleegers K; Van Broeckhoven C; De Deyn PP; Streffer JR; Mercken M; Engelborghs S
    J Alzheimers Dis; 2015; 45(3):813-22. PubMed ID: 25633670
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Does Caffeine Consumption Modify Cerebrospinal Fluid Amyloid-β Levels in Patients with Alzheimer's Disease?
    Travassos M; Santana I; Baldeiras I; Tsolaki M; Gkatzima O; Sermin G; Yener GG; Simonsen A; Hasselbalch SG; Kapaki E; Mara B; Cunha RA; Agostinho P; Blennow K; Zetterberg H; Mendes VM; Manadas B; de Mendon A
    J Alzheimers Dis; 2015; 47(4):1069-78. PubMed ID: 26401784
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mass spectrometry is a multifaceted weapon to be used in the battle against Alzheimer's disease: Amyloid beta peptides and beyond.
    Grasso G
    Mass Spectrom Rev; 2019 Jan; 38(1):34-48. PubMed ID: 29905953
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Decreased beta-amyloid1-42 and increased tau levels in cerebrospinal fluid of patients with Alzheimer disease.
    Sunderland T; Linker G; Mirza N; Putnam KT; Friedman DL; Kimmel LH; Bergeson J; Manetti GJ; Zimmermann M; Tang B; Bartko JJ; Cohen RM
    JAMA; 2003 Apr 23-30; 289(16):2094-103. PubMed ID: 12709467
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Establishing pre-analytical requirements and maximizing peptide recovery in the analytical phase for mass spectrometric quantification of amyloid-β peptides 1-42 and 1-40 in CSF.
    Forgrave LM; van der Gugten JG; Nguyen Q; DeMarco ML
    Clin Chem Lab Med; 2022 Jan; 60(2):198-206. PubMed ID: 34881836
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Amyloid-β as a biomarker for Alzheimer's disease: quantification methods in body fluids.
    Galozzi S; Marcus K; Barkovits K
    Expert Rev Proteomics; 2015 Aug; 12(4):343-54. PubMed ID: 26153725
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pre-analytical and analytical factors influencing Alzheimer's disease cerebrospinal fluid biomarker variability.
    Fourier A; Portelius E; Zetterberg H; Blennow K; Quadrio I; Perret-Liaudet A
    Clin Chim Acta; 2015 Sep; 449():9-15. PubMed ID: 26141614
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Amyloid-β-Secondary Structure Distribution in Cerebrospinal Fluid and Blood Measured by an Immuno-Infrared-Sensor: A Biomarker Candidate for Alzheimer's Disease.
    Nabers A; Ollesch J; Schartner J; Kötting C; Genius J; Hafermann H; Klafki H; Gerwert K; Wiltfang J
    Anal Chem; 2016 Mar; 88(5):2755-62. PubMed ID: 26828829
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The use of mass spectrometry to study amyloid-β peptides.
    Grasso G
    Mass Spectrom Rev; 2011; 30(3):347-65. PubMed ID: 21500241
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Competitive electrochemical immunoassay for detection of β-amyloid (1-42) and total β-amyloid peptides using p-aminophenol redox cycling.
    Liu L; He Q; Zhao F; Xia N; Liu H; Li S; Liu R; Zhang H
    Biosens Bioelectron; 2014 Jan; 51():208-12. PubMed ID: 23962708
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.